The Mount Sinai Health System is at the forefront of skin cancer research, conducting both clinical trials and basic science studies to advance our understanding of skin cancers and to develop new treatments. With a prominent team of basic scientists and translational researchers recruited from leading institutions, our goal is to move beyond the limitations of standard therapy.

In the area of melanoma, for example, our researchers are working to identify therapies for stage IV disease that provide durable benefit in a very high percentage of people. For early stage melanomas, we are developing tests to predict the likelihood of recurrence and investigating treatment approaches to decrease the chances that a melanoma will come back. We work with immunologists, molecular biologists, cell biologists, and geneticists to make novel discoveries.

Mount Sinai has a robust clinical trials program for skin cancer. We are actively enrolling patients in a number of current studies.